Enlyte

Enlyte is the brand Stone Point Capital put on top of three companies it already owned: Mitchell, Genex and Coventry. The launch announcement was October 13, 2021. The combined organisation employs roughly 6,000 people and is headquartered in San Diego.

Who owns it. Stone Point Capital, through its Trident private-equity funds. Stone Point bought Mitchell from KKR and Elliott Management in April 2018. It bought Genex from Apax Partners the same year and merged Genex into Mitchell on November 1, 2018. Mitchell|Genex then bought Coventry's workers' comp services business from CVS Health on August 1, 2020. Enlyte is the marketing name for that three-step roll-up, not a new transaction. KKR is not the parent — KKR was the seller in 2018. The phidea consolidation map (see the US insurance software consolidation 2022-2025 essay) frames this as the largest single roll-up of the recent cycle, and that is correct on substance even though the parent and the assembly dates predate the 2022-2025 window.

What each piece actually does.

• Mitchell is one of the two US auto-claims networks (the other is CCC). It runs estimating software for collision repair shops and insurers, total-loss valuation, and casualty bill review on the bodily-injury side. Public scale on the Mitchell site: 300+ insurance company customers, 30,000+ collision repair facilities, 50M+ transactions per year. Named carriers in press include Progressive, State Farm (Select Service), Lemonade and Texas Farm Bureau.

• Genex is workers' comp medical management — case managers (nurses) who follow an injured worker through treatment, plus utilisation review (deciding whether a requested treatment is medically necessary under the state's workers' comp rules), peer review, and historically independent medical exams. The IME business spun out as a separate company called Emperion in 2024.

• Coventry is the workers' comp PPO network: a panel of doctors, hospitals and ancillary providers contracted at workers' comp fee schedules. Coventry came over from CVS Health, which had inherited it through Aetna. The network is the single largest piece of fee-schedule plumbing in US workers' comp.

• Enlyte Pharmacy Solutions is the in-house pharmacy benefit manager (PBM = the company that processes drug claims and negotiates pricing with pharmacies). Enlyte's pitch is that it does workers' comp and auto casualty only — not commercial health — so the clinical rules are tuned to injured-worker care.

Stacked together, you get the full workers' comp medical-cost spend: the network the worker is steered to (Coventry), the nurse following the case (Genex), the pharmacist filling the script (Enlyte PBM), and the utilisation reviewer deciding what gets approved (Genex). On the auto side you get the estimate (Mitchell) and the bill review (Mitchell casualty).

Why Stone Point built this. Workers' comp claims medical spend in the US is roughly $30 billion per year, and historically a single carrier or third-party administrator (TPA) bought network access from one vendor, case management from a second, PBM from a third, bill review from a fourth. The Enlyte thesis is that one combined supplier can sell the bundle and capture more of that spend per claim. Whether the bundle wins at procurement is the open question — see the limitations below.

The persistent sale process. In December 2021, Axios reported that Stone Point was running a sale process for Enlyte at roughly $450M EBITDA, implying a multi-billion-dollar deal. As of May 2026, no sale has been announced. Four-plus years on the block is unusually long for a private-equity asset. The most plausible reads are that the bundle thesis has not closed at the price Stone Point wants, or that the strategic buyer pool (CVS, UnitedHealth, the big insurance services holdings) has been thinned by their own restructurings.

The 2024 IME spin-out. In March 2024, Stone Point and former Genex leaders agreed to carve out the independent medical exam business as a new standalone company called Emperion, taking around 350 employees with it. Emperion is owned by Stone Point through the same Trident funds that own Enlyte. The integrated-bundle story Enlyte told at brand launch in 2021 is narrower in 2026 than it was at the start.

Where it sits in the vendor map. In auto estimating, Mitchell is the modern rung alongside CCC, with Tractable and other AI-native players sitting on top of Mitchell's rails through partnerships rather than replacing them. In workers' comp medical management, Genex/Coventry/Enlyte PBM is the largest single bundle in the market; the closest equivalents are Sedgwick, Paradigm and One Call, but none of those holdings combines all four pieces (network + case management + UR + PBM) under one roof in the way Enlyte does. In workers' comp predictive analytics — claim severity scoring, return-to-work prediction — Enlyte is not the leader; that space belongs to CLARA Analytics and Gradient AI.

What this means for a US carrier or TPA buying in 2026. You can buy any of the four pieces standalone. The bundle discount exists on paper. The procurement reality is that most large carriers already have multi-vendor contracts in place and unwinding them to consolidate on Enlyte requires a multi-year migration with real switching cost. The pending sale process is a material consideration on contract length — a 5-year medical-management contract signed in 2026 will likely span at least one ownership change.